Literature DB >> 18097593

Sp1 is involved in 8-chloro-adenosine-upregulated death receptor 5 expression in human hepatoma cells.

Minmin Sun1, Jinchun Zhang, Shilian Liu, Yanxin Liu, Dexian Zheng.   

Abstract

8-Chloro-adenosine (8-Cl-Ado) is an adenosine derivative, which inhibits proliferation and induces apoptosis in various tumor cells. Subtoxic concentration of 8-Cl-Ado sensitizes human hepatoma cells to tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-triggered apoptosis. However, the molecular mechanism by which TRAIL cytotoxicity is amplified by 8-Cl-Ado is unknown. In the present study, we demonstrated by Western blot and real-time PCR that 8-Cl-Ado selectively up-regulated death receptor 5 (DR5), but not death receptor 4 (DR4), at both protein and RNA levels in human hepatoma cell line BEL-7402. Analysis of the transcriptional regulation of DR5 expression by using Dual-Luciferase reporter assay system demonstrated that the 5'-flanking fragment -207 to -145 upstream to the ATG site within the DR5 promoter region was responsible for the 8-Cl-Ado-upregulated DR5 expression. Electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) confirmed that 8-Cl-Ado treatment facilitated transcription factor Sp1 binding to its cis-element -198/-189 in the DR5 promoter, suggesting that Sp1 is at least one of the 8-Cl-Ado-responsive transcription factors. However, we observed that nuclear factor kappaB (NF-kappaB) activity remained invariable in the cells treated with 8-Cl-Ado. These data allowed us to draw a conclusion that 8-Cl-Ado-enhanced DR5 expression is regulated by Sp1 binding to the -198/-189 cis-element in DR5 promoter without affecting NF-kappaB activity in the hepatoma cells. This study may shed light on further screening the regulators of DR5 expression and developing novel therapeutic drugs for liver cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18097593

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  Wogonin and related natural flavones overcome tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein resistance of tumors by down-regulation of c-FLIP protein and up-regulation of TRAIL receptor 2 expression.

Authors:  Jie Ding; Gernot Polier; Rebecca Köhler; Marco Giaisi; Peter H Krammer; Min Li-Weber
Journal:  J Biol Chem       Date:  2011-11-15       Impact factor: 5.157

Review 2.  Hepatocellular carcinoma: targeting of oncogenic signaling networks in TRAIL resistant cancer cells.

Authors:  Sundas Fayyaz; Ilhan Yaylim; Saime Turan; Sobia Kanwal; Ammad Ahmad Farooqi
Journal:  Mol Biol Rep       Date:  2014-07-19       Impact factor: 2.316

3.  Inhibition of Notch1 signaling overcomes resistance to the death ligand Trail by specificity protein 1-dependent upregulation of death receptor 5.

Authors:  A Fassl; K E Tagscherer; J Richter; J De-Castro Arce; C Savini; F Rösl; W Roth
Journal:  Cell Death Dis       Date:  2015-10-15       Impact factor: 8.469

4.  A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase.

Authors:  Venturina Stagni; Simonetta Santini; Daniela Barilà
Journal:  Cancers (Basel)       Date:  2012-04-05       Impact factor: 6.639

5.  Altered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndrome.

Authors:  J X Zou; D E Rollison; D Boulware; D-T Chen; E M Sloand; L V Pfannes; J J Goronzy; F Bai; J S Painter; S Wei; D Cosgrove; A F List; P K Epling-Burnette
Journal:  Leukemia       Date:  2009-03-12       Impact factor: 12.883

6.  Calmodulin antagonists promote TRA-8 therapy of resistant pancreatic cancer.

Authors:  Kaiyu Yuan; Sun Yong; Fei Xu; Tong Zhou; Jay M McDonald; Yabing Chen
Journal:  Oncotarget       Date:  2015-09-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.